BioNTech (NASDAQ:BNTX) Shares Gap Down – What’s Next?

BioNTech SE (NASDAQ:BNTX) shares gapped down before the market opened on Friday . The stock had previously closed at $103.56, but opened at $99.89. BioNTech shares last traded at $97.91, with a volume of 505,019 shares changing hands.

Wall Street Analysts Forecast Growth

BNTX has been the subject of a number of research reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $171.00 price objective on shares of BioNTech in a research report on Thursday. HSBC lifted their price objective on BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a report on Monday, October 7th. Bank of America boosted their price target on BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, September 16th. Deutsche Bank Aktiengesellschaft lifted their price objective on BioNTech from $95.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, September 19th. Finally, The Goldman Sachs Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and increased their target price for the stock from $90.00 to $137.00 in a research report on Friday, November 8th. Four equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $137.54.

BioNTech Price Performance

The stock has a market cap of $23.76 billion, a price-to-earnings ratio of -45.62 and a beta of 0.26. The company has a 50 day simple moving average of $113.34 and a 200-day simple moving average of $97.10. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $514.08 million. During the same period in the previous year, the firm posted $0.73 EPS. The company’s revenue for the quarter was up 38.9% on a year-over-year basis. Research analysts expect that BioNTech SE will post -3.47 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. GAMMA Investing LLC increased its position in shares of BioNTech by 21.7% during the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock worth $74,000 after purchasing an additional 111 shares during the last quarter. Covestor Ltd raised its position in BioNTech by 47.2% during the first quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after acquiring an additional 133 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in shares of BioNTech by 2.3% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 9,800 shares of the company’s stock valued at $904,000 after purchasing an additional 223 shares during the period. EverSource Wealth Advisors LLC lifted its stake in BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after purchasing an additional 252 shares during the last quarter. Finally, Capital International Sarl grew its holdings in BioNTech by 1.3% during the first quarter. Capital International Sarl now owns 24,058 shares of the company’s stock worth $2,219,000 after purchasing an additional 310 shares during the period. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.